A UK digital health company is validating a mobile health platform that is more patient-centric but approved by subject matter experts and working alongside leading clinicians. It allows for multiple users and multiple languages at all times. Licensing is being sought with pharma, biotech, medtech companies in vascular, cancer, neurological disease. At the same time, partners’ clinical pathways can be enhanced and validated quickly in the UK under a technical cooperation.
A UK digital health company has launched a mobile health platform that is broader than the ones on the market. Existing solutions tend to deliver for a single specific condition or user. This new app and platform is more patient-centric. It engages the family much more, and it gives the patient more user rights. They can share exactly what they want, with whom they want. The company has 15 conditions currently built and the app works 13 languages simultaneously which offers the opportunity to think global when it comes to data studies. The company is collaborating with clinicians in the National Health Service, and a large company, in the UK, and is laying out plans for work abroad. Pathways for cardiovascular disease, cancer and neurological conditions have been elaborated with and approved by leading clinicians. The capture, sharing and analysis allow for lots of data gathering and analysis formats (structured, data, and graphical, see the Pictures), so that very different patients find it easy to use. The company’s offer goes both ways. They are keen to work with sizable companies sponsoring digital health solutions around vascular disease, cancer, neurology (upon request, further conditions can be added in a very time-efficient manner). This can be licensed out very quickly. At the same time, the company can help validate joint programmes in the UK, enhanced by the new platform in collaboration with UK experts.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
Type of partner sought: industry Specific area of activity of partner sought: Pharma, biotech, medtech companies. Role of partner sought: A collaboration in vascular disease prevention; prostate cancer outpatient monitoring; or neurological research. In a reverse direction, partners’ programmes can be enhanced and developed further under a technical co-operation, and validated clinically in the UK.
Stage of Development: